RT Journal Article
SR Electronic
T1 Brain age as a surrogate marker for information processing speed in multiple sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.03.21262954
DO 10.1101/2021.09.03.21262954
A1 S Denissen
A1 DA Engemann
A1 A De Cock
A1 L Costers
A1 J Baijot
A1 J Laton
A1 IK Penner
A1 M Grothe
A1 M Kirsch
A1 MB D’hooghe
A1 M D’Haeseleer
A1 D Dive
A1 J De Mey
A1 J Van Schependom
A1 DM Sima
A1 G Nagels
YR 2021
UL http://medrxiv.org/content/early/2021/09/07/2021.09.03.21262954.abstract
AB Background Data from neuro-imaging techniques allow us to estimate a brain’s age. Brain age is easily interpretable as “how old the brain looks”, and could therefore be an attractive communication tool for brain health in clinical practice. This study aimed to investigate its clinical utility.Objectives To investigate the relationship between brain age and information processing speed in MS.Methods A ridge-regression model was trained to predict age from brain MRI volumetric features and sex in a healthy control dataset (HC_train, n=1690). This model was used to predict brain age in two test sets: HC_test (n=50) and MS_test (n=201). Brain-Predicted Age Difference (BPAD) was calculated as BPAD=brain age minus chronological age. Information processing speed was assessed with the Symbol Digit Modalities Test (SDMT).Results Brain age was significantly related to SDMT scores in the MS_test dataset (r=-0.44, p<.001), and contributed uniquely to variance in SDMT beyond chronological age, reflected by a significant correlation between BPAD and SDMT (r=-0.21, p=0.003) and a significant weight (−0.21, p=0.011) in a multivariate regression equation with age.Conclusions Brain age is a candidate biomarker for information processing speed in MS and an easy to grasp metric for brain health.Competing Interest StatementStijn Denissen is an industrial PhD candidate in collaboration with icometrix. Diana Sima is a senior researcher at icometrix. Guy Nagels is on a 10% secondment from the UZ Brussel to icometrix as medical director, and is a minority shareholder of icometrix. Lars Costers is an employee of icometrix.Funding StatementThe authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Stijn Denissen is funded by a Baekeland grant appointed by Flanders Innovation and Entrepreneurship (HBC.2019.2579, www.vlaio.be), Guy Nagels received research grants from Biogen and Genzyme, and is a senior clinical research fellow of the FWO Flanders (1805620N, www.fwo.be), and Jeroen Van Schependom is a senior research fellow of VUB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants of the BRUMEG study, Brussels, all provided their written informed consent prior to MRI assessment. The study protocol (B.U.N. 143201423263) was approved by the ethical committee of the UZ Brussel (Commissie Medische Ethiek (O.G. 016), Reflectiegroep Biomedische Ethiek) on 2015/02/25. For the patients from Greifswald, Germany, the study was approved by the ethics committee of the Medical Faculty of the University of Greifswald (BB159/18), and all participants gave their written informed consent. HC_train data consists of publicly available data originating from other projects, listed in supplementary table S1. Ethical approval was received by each project separately.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData that was used to train our model was derived from publicly available repositories, of which the details can be found in the manuscript. Availability of the other data is subject to discussion with the senior author and may be limited by the ethics approval.